Dna repair drugs market analysis | Coherent Market Insights - PowerPoint PPT Presentation

About This Presentation

Dna repair drugs market analysis | Coherent Market Insights


Read here the latest updates on the Dna repair drugs market analysis published by the CMI team. – PowerPoint PPT presentation

Number of Views:57


Transcript and Presenter's Notes

Title: Dna repair drugs market analysis | Coherent Market Insights

Coherent Marketing Insights
  • Market Research Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • Covid-19 Impact Tracker

  • DNA Repair Drugs Market, by Drug (Niraparib
    (Zejula), Olaparib (Lynparza), Rucaparib
    (Rubraca), Talazoparib (Talzenna), and Others),
    by Application (Ovarian cancer, Fallopian Tube
    cancer, Peritoneal cancer, Breast cancer and
    Gastric cancer) by Distribution Channel (Hospital
    Pharmacies, Retail Pharmacies, and Online
    Pharmacies), and by Region (North America, Latin
    America, Europe, Asia Pacific, Middle East, and
    Africa) Size, Share, Outlook, and Opportunity
    Analysis, 2018 2026

  • DNA repair drugs are used in repairing damaged
    DNA and for treating cancers. DNA damage results
    in genetic disorders, however the human body has
    its own mechanisms to correct the DNA sequence.
    DNA repair drugs such as PARP inhibitors and
    other DNA repair drugs help to treat diseases
    with genetic aberrations.
  • The global DNA repair drugs market size was
    valued at US 461.3 Mn in 2017, and is expected
    to exhibit a CAGR of 32.4 over the forecast
    period (20182026).

Figure 1. Global DNA Repair Drugs Market Value
(US Mn), by Region, 2018
  • Increasing incidence of cancer, rising government
    initiatives to promote awareness for cancer
    treatment, and expansion strategies by
    manufacturers to increase and expand their
    product portfolio in the international markets
    are factors propelling growth of the global DNA
    repair drugs market
  • Increasing incidence of cancer is expected to
    drive the global DNA repair drugs market growth
    over the forecast period. According to the World
    Cancer Research Fund Internationals report in
    2018, breast cancer accounted for the second
    highest number of cancer cases (2,088,849 new
    cases) across the globe in 2018. According to
    GLOBOCAN, 43.6 new cases of breast cancer were
    registered in Asia Pacific in 2018.
  • Moreover, increasing drug approval by key players
    in order to address demand for efficient
    therapeutics, is expected to propel growth of the
    market over the forecast period. In October 2018,
    Pfizer Inc. received the U.S. Food and Drug
    Administration (FDA) approval for Talazoparib
    (Talzenna) for treating patients with HER2
    (negative locally advanced or metastatic breast

Figure 2. Global DNA Repair Drugs Market Share
(), by Drug Type, (2018-2026)

Rising prevalence of cancer, as well as
increasing collaborations and acquisitions by key
players is expected to boost the market growth
  • North America is expected to dominate the global
    DNA repair drugs market over the forecast period
    owing to increasing incidence of cancer.
    According to the American Cancer Society, in
    2018, an estimated 266,120 new cases of invasive
    breast cancer were diagnosed in the U.S.
    Moreover, increasing demand for cancer treatments
    is expected to drive growth of the DNA repair
    drugs market in the region.
  • Market players are engaged in research and
    development activities in order to meet the
    rising demand DNA repair drugs. In May 2019,
    Clovis Oncology, Inc., collaborated with
    Bristol-Myers Squibb Company and Foundation
    Medicine Inc. to initiate phase II study for
    evaluating rucaparib in combination with
    nivolumab in patients with high-grade serous
    carcinoma (HGSC) or endometroid ovarian cancer.

Key Players
  • Major players operating in the global DNA repair
    drugs market are AstraZeneca Plc., Johnson
    Johnson, GlaxoSmithKline plc., Pfizer, Inc.,
    Clovis Oncology Inc., AbbVie Inc., Bristol -
    Myers Squibb, Merck KGaA, Genentech, Inc., Repare
    Therapeutics Inc., Karyopharm Therapeutics Inc.,
    Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui
    Medicine Co., Ltd.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Referance https//www.coherentmarketinsights.com/

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions. We are headquartered
    in India, having office at global financial
    capital in the U.S. Our client base includes
    players from across all business verticals in
    over 150 countries worldwide.
  • What We ProvideCustomized Market Research
    AnalysisIndustry Analysis ServicesBusiness
    Consulting ServicesLong Term Engagement
    ModelCountry Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt. LTD.Coherent
    Market Insights 1001 4th Ave, 3200 Seattle, WA
    98154, U.S.Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

Thank You
  • Kindly Follow CMI Social Media Profiles for the
    latest Company Updates.
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
Write a Comment
User Comments (0)
About PowerShow.com